This suggests that while there may be an association with thyroid disorders, the exact nature of this relationship warrants further investigation
This is actually the ideal pattern
Strong adoption of advanced GLP-1 therapies by healthcare providers, coupled with growing clinical evidence supporting cardiovascular and weight-loss benefits, is driving market demand
Last month (May 2025), Novo Nordisk and Septerna, a San Francisco, California-based bio/pharmaceutical company focused on GCPRs, formed an exclusive global collaboration and license agreement to discover, develop, and commercialize oral small-molecule medicines for treating obesity, Type 2 diabetes, and other cardiometabolic diseases, in a deal worth up to $2.2 billion ($200 million upfront and near-term funding and $2 billion in milestone payments)
So the main concern is not a proven dangerous interaction for every person